Mesangial proliferative glomerulonephritis with or without IgA deposits: the morphological characters in psoriasis vulgaris.
Jiao Y, Xu H, Li H, Li X.
Nephron Clin Pract. 2008;108(3):c221-5. doi: 10.1159/000119716. Epub 2008 Mar 7.
PMID:18332636
Expression and clinical significance of thrombospondin-1 and plasminogen activator inhibitor-1 in patients with mesangial proliferative glomerulonephritis.
Pan C, Zhou C, Shan A, Chen N.
Ann Palliat Med. 2020 Sep;9(5):3187-3193. doi: 10.21037/apm-20-1291. Epub 2020 Aug 31.
PMID:32921106
Pathological regression by angiotensin II type 1 receptor blockade in patients with mesangial proliferative glomerulonephritis.
Ohtake T, Oka M, Maesato K, Mano T, Ikee R, Moriya H, Kobayashi S.
Promising response of proliferative glomerulonephritis with monoclonal IgG deposits to low-dose daratumumab: a case report.
Xu H, Huang Y, Dong L, Yu H, Lin B.
Front Med (Lausanne). 2024 Jul 24;11:1360979. doi: 10.3389/fmed.2024.1360979. eCollection 2024.
PMID:39114824
Mesangial proliferative glomerulonephritis associated with progressive amyloid deposition in hamsters experimentally infected with Leishmania donovani.
Oliveira AV, Roque-Barreira MC, Sartori A, Campos-Neto A, Rossi MA.
Am J Pathol. 1985 Aug;120(2):256-62.
PMID:4025511
Diffuse proliferative glomerulonephritis--how many types?